BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 22, 2014
View Archived Issues
Chemical modification of a marketed HIV protease inhibitor leads to new immunomodulatory agent
Read More
Mitochondrial-targeted nanoparticle drug delivery to overcome anticancer drug resistance
Read More
MYOS and Cloud Pharmaceuticals to develop drugs targeting sarcopenia and cachexia
Read More
Hopp acquires Lohmann Therapie-Systeme shares from Novartis and BWK
Read More
Celgene to initiate phase II study of CC-220 in cutaneous sarcoidosis
Read More
Novel tau aggregation inhibitors for the treatment of tauopathies
Read More
Novel O-GlcNAcase inhibitors prepared by Alectos Therapeutics and Merck & Co.
Read More
AbbVie's multidrug regimen for HCV evaluated in patients with HIV co-infection
Read More
OriBase Pharma discloses novel multi kinase inhibitors
Read More
Hanmi signs contract with Actavis for Hyalrheuma
Read More
Sandoz to commercialize Anacor's Kerydin in U.S.
Read More
Japan Tobacco describes new HIV integrase inhibitors
Read More
Ube Industries discloses novel LPA1 receptor antagonists
Read More
Merck & Co. designs novel adenosine receptor antagonists for PD
Read More
Nippon Zoki synthesizes novel agents for neuropathic pain
Read More
MARCH8 protein blocks HIV-1 infection
Read More
Daiichi Sankyo to test DS-5573a in patients with solid tumors
Read More
Strides Arcolab makes strategic investment in U.S. biosimilar developer Oncobiologics
Read More
Sanofi plans first-in-human study of SAR-408701 for advanced solid tumors
Read More
Regulus Therapeutics' anti-miR-21 oligonucleotide awarded FDA orphan drug status for Alport syndrome
Read More
Genocea initiates phase II study of GEN-003 HSV-2 immunotherapy
Read More
Dipexium Pharmaceuticals initiates pivotal phase III trials of topical peptide antibiotic
Read More
Pivotal study of PRT-201 for hemodialysis vascular access in patients with chronic kidney disease
Read More
FDA grants breakthrough therapy designation to Aduro's pancreatic cancer combination immunotherapy
Read More
FDA grants priority review to Avastin sBLA in ovarian cancer
Read More